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FGF-2 counteracts loss of TGFβ affected cells from rat lens explants: 
Implications for PCO (after cataract) 
Abstract 
Purpose: While cataract surgery initially benefits most patients, many suffer secondary loss of vision 
because of posterior capsule opacification (PCO). Lens epithelial cells left behind at surgery become 
aberrant and migrate into the light path. TGF-beta (TGFβ) appears to play a key role in this process by 
inducing the cells to undergo an epithelial-mesenchymal transition. Paradoxically, it also typically induces 
them to undergo apoptotic death. The present study was undertaken to investigate the hypothesis that 
FGF plays a role in PCO formation by promoting the survival of abnormal cells with PCO-like 
characteristics. 
Methods: Rat lens epithelial explants were cultured for one day with TGFβ2 (25-100 pg/ml) then in control 
medium with or without FGF-2 (5-100 ng/ml) for up to 31 days, with assessment by light and scanning 
electron microscopy and immunolocalization. 
Results: Survival of TGFβ treated cells was promoted by FGF-2 but not by EGF, PDGF, IGF, or HGF. In the 
absence of FGF virtually all cells were lost from explants within 5 days. However, when FGF was included 
cells remained viable throughout culture. These cells, which no longer expressed the lens epithelial 
marker Pax6, exhibited immunoreactivity for non-lens cell proteins associated with PCO (α-smooth 
muscle actin, type I collagen, and fibronectin) and also β-crystallin. FGF inclusion also promoted ECM 
production, multilayering, and plaque formation, features of PCO known to contribute to visual loss. 
Conclusions: This study points to a key role for FGF in the etiology of PCO and suggests that FGF 
inhibitors may be useful in preventing PCO. 
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 The lens of the eye is a flattened transparent globe,
through which light must pass on its way to the retina. It con-
sists of only two cell types, elongated fiber cells covered ante-
riorly by a monolayer of epithelial cells. Cataract, or loss of
lens transparency, accounts for about 42 percent of all blind-
ness. Globally, more than 20 million people now have cata-
ract, a number that may double by 2010 because of increasing
life expectancy and the strong association between cataract
and aging [1]. Surgery is the only treatment available at present.
The preferred procedure involves removing a circular ante-
rior portion of the lens capsule (a thick basement membrane
that completely encloses the lens), breaking up and removing
most of the lens tissue and placing a synthetic lens implant
(intraocular lens, IOL) into the empty capsular bag that re-
mains.
While most patients benefit from this treatment initially,
within 5 years of surgery about 20-40% suffer a secondary
loss of vision because of posterior capsule opacification (PCO),
also known as after-cataract [2]. PCO can be treated using an
Nd:YAG laser; however, this procedure is not without risk to
sight, adds substantially to the cost of treatment, and is not
readily available in the developing world where the incidence
of cataract is high [3]. PCO therefore remains a significant
clinical problem.
PCO arises from lens epithelial cells left behind at the
time of cataract surgery [3-6]. These cells, which are initially
associated only with the remnants of the anterior capsule, mi-
grate onto the posterior capsule underlying the IOL and into
the light path. Many undergo epithelial-mesenchymal transi-
tion resulting in the formation of fibroblasts and spindle-like
myofibroblasts. Impairment of vision is thought to result from
myofibroblast-induced wrinkling of the central region of the
posterior capsule and/or formation of opaque multilayered
plaques, strands, and aggregations of cells (Elschnig’s pearls)
in this region [3-5]. Abundant deposition of ECM by aberrant
cells may also contribute significantly to visual impairment
[3].
TGF-beta (TGFβ) has been shown in vitro to initiate cel-
lular and molecular changes in lens epithelial cells that are
associated with PCO development, including myofibroblast
formation, wrinkling of the lens capsule, induction of fibro-
blast markers, and deposition of ECM. First highlighted in
studies of rat lens epithelial explants [7], this finding has since
been confirmed and extended using a variety of rat, mouse,
rabbit, bovine, canine, and human models, both in vitro and in
vivo [8-17]. Such studies, together with others indicating that
TGFβ is potentially available to lens cells in situ, point to a
key role for TGFβ in the aetiology of PCO [10,16-24].
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Paradoxically, TGFβ also characteristically induces lens
cells to undergo apoptosis [7,9,25-28] leading to rapid loss of
virtually all cells from TGFβ treated lens epithelial explants
during culture [9,28]. While a degree of apoptosis occurs in
association with PCO development [27], a major feature of
this condition is survival of many cells that show changes typi-
cally induced by TGFβ. Thus it is unlikely that PCO develop-
ment results from the action of TGFβ alone.
FGF has been shown to exacerbate TGFβ induced ante-
rior subcapsular cataract formation in cultured rat lenses [29].
In addition, it has been noted that explants from rats less than
13 days old do not respond to TGFβ at all unless fibroblast
growth factor (FGF) is included [7,11]. Inclusion of FGF in-
duces upregulation of TGFβ receptors, which are virtually lack-
ing at that stage [11]. Under the latter conditions, large num-
bers of abnormal cells survive instead of apoptosing [7], sug-
gesting that FGF may also act as a survival factor. FGF is
known to fulfill this role for a wide variety of cell types [30].
FGF-1 and the more potent isoform FGF-2 are continu-
ously present in the normal lens environment and members of
the FGF family are known to play a unique role in establish-
ing and maintaining normal lens structure and function [31-
33]. In vitro, the effect of FGF-2 on normal lens epithelial
cells has been shown to vary with concentration. Prolifera-
tion, migration, and fiber differentiation occur progressively
as the concentration is increased [31]. FGF also initiates the
differentiation of lens epithelial cells into fiber cells in vivo.
This occurs as cells pass from the anterior to the posterior
chamber of the eye, where they encounter the FGF-enriched
vitreous humor [31].
The present study was undertaken to investigate the hy-
pothesis that FGF plays a role in PCO formation by promot-
ing the survival of abnormal cells with PCO-like characteris-
tics. The effect of FGF-2 on cell survival was investigated in
rat lens explants that had been exposed to TGFβ. In short-
term experiments, it was found that FGF counteracted TGFβ
induced cell loss, an effect that was not mimicked by other
growth factors tested. In addition, in longer-term experiments,
it was found that cells that survived in TGFβ/ GF treated ex-
plants exhibited a range of features and behaviors characteris-
tic of human PCO. Explants were assessed for morphological
changes and by immunolocalization of protein markers and
scanning electron microscopy (SEM).
METHODS
 Recombinant human TGFβ2 was obtained from Genzyme
TABLE 1. COMPARISON OF EFFECTS OF FGF AND OTHER GROWTH FACTORS ON TGFΒ TREATED LENS EPITHELIAL EXPLANTS
                                    TGFβ   TGFβ    TGFβ    TGFβ    TGFβ
    Response      Control   TGFβ    +FGF   +EGF    +PDGF   +IGF    +HGF
  -------------   -------   -----   ----   -----   -----   -----   -----
Day 3
  Wrinkling          -      ++++    -      +++     +++     ++      ++++
  Spindle cells      -      ++      -/+    ++      ++      +++     ++
  Blebbing           -      ++++    -      ++++    ++++    ++++    ++++
  Cell loss          -      +       -/+    +       +       +       +
Day 4
  Wrinkling          -      ++++    -      ++++    ++++    ++      ++++
  Spindle cells      -      *       ++     *       *       *       *
  Blebbing           -      +++++   +      +++++   +++++   +++++   +++++
  Cell loss          -      +++     -/+    +++     +++     +++     +++
Day 6
  Blebbing          -/+     *       +      +++++   *       *       *
  Cell loss         -/+     +++++   +      +++++   ++++    ++++    +++++
Number of
explants             4        6      8      4       3       5       6
Explants were cultured with 50 pg/ml TGFβ for one day then, after replacing medium, with FGF, EGF, PDGF, IGF, or HGF, at the concentra-
tions indicated in the legend of Figure 3, or without further addition. Controls received no growth factors throughout the cultre period. Four
categories of response were assessed: wrinkling of the lens capsule, spindle cell formation, cell surface blebbing, and cell loss. The number of
pluses indicates the proportion of the explant exhibiting a particular feature. A dash indicates no change. An asterisk indicates the feature could
not be assessed due to extensive cell loss. Explants that were initially poorly covered with cells (10% or less) were excluded from this
assessment. Throughout the culture period, control explants remained in cobblestone arrays typical of the normal lens epithelium, wher as
cells in the other groups, although still monolayered, were often elongated and irregularly arrayed. Prior to day 3 the only changes noted were
a slight wrinkling in the central region and scattered spindle cell formation in some explants in the TGFβ and TGFβ plus EGF groups. By day
9, all explants in the TGFβ and the TGFβ plus EGF, TGFβ plus PDGF, TGFβ plus IGF, and TGFβ plus HGF groups were virtually devoid of
cells.
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(Cambridge, MA), and FGF-2, PDGF-AA, IGF-1, EGF, and
HGF were from PeproTech (Rock Hill, NJ). The factors were
reconstituted and stored according to the manufacturer’s in-
structions. Working solutions were prepared just before use.
Lens epithelial explant cultures:  All experimental proce-
dures conformed to the Institute for Laboratory and Animal
Research (Guide for the Care and Use of Laboratory Animals).
Lenses were derived from weanling (19-22 day old) Wistar
rats. Explants were prepared by peeling the epithelium from
the lens and pinning it out in a 35 mm culture dish, cell sur-
face uppermost, in serum free M199 medium containing bo-
vine serum albumin and antibiotics (control medium [9]) or
the same medium buffered with 20 mM HEPES. Unless oth-
erwise indicated, after replacing medium with 1 ml control
medium, 25-100 pg/ml TGFβ was added and explants were
cultured at 37 °C in 5% CO
2
/air. One day later, the medium
was discarded and replaced with 1 ml control medium and 5-
100 ng/ml FGF was added. In early experiments, explants were
washed twice with control medium before replacing medium.
This washing and inclusion of HEPES during setting up did
not appear to influence the outcome. TGFβ and/or growth fac-
tors were omitted from controls. In some experiments, FGF
was replaced with PDGF, IGF, EGF, or HGF at the doses indi-
cated. Explants were cultured for 3-31 days, with medium
change every 4-5 days and re-addition of FGF if added ini-
tially.
Explants were monitored by phase contrast microscopy
for the period specified then fixed in 100% ethanol (if to be
used for Pax6 immunolocalization) or Carnoy’s fixative (3:1
ethanol:acetic acid) and stored in 70% ethanol. Before or af-
ter fixing, explants were photographed by phase contrast or
using a DMIL inverted microscope with Integrated Modula-
tion Contrast and a DC200 digital camera (Leica
Microsystems, Wetzlar, Germany). Fixed explants were used
for immunolocalization, as whole mounts or after embedding
in paraffin, or processed for SEM.
Histology and immunolocalization:  For paraffin embed-
ded samples, each explant was sectioned (6 µm) serially per-
pendicular to the lens capsule and every fifth slide was stained
with hematoxylin and eosin. Centrally located sections were
photographed and adjacent sections were used for
immunolocalization. Prior to immunolocalization, whole
mounts and sections were rehydrated with PBS-0.1% BSA.
α-Smooth muscle actin (αSMA) and fibronectin were local-
ized by a double labeling technique as described elsewhere
[29], using mouse αSMA antibody and goat anti-rat
fibronectin, visualized with Alexa 488-conjugated anti-mouse
antibody (Molecular Probes, Eugene, OR) and Cy3-conjugated
anti-goat antibody (Zymed, San Francisco, CA). Alternatively,
explants were double labeled using αSMA antibody, as above,
with rabbit anti-rat type I collagen, anti-β-crystallin [29], or
anti-Pax6 (Covance, Berkeley, CA; 1:500) visualized using
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Figure 1. The effect of FGF on TGFβ treated lens
epithelial explants.  Explants were cultured without
TGFβ (A,B) or with TGFβ (C-F) for 1 day. Medium
was then replaced without further addition of TGFβ
and FGF was added to some cultures (B,D,F).
TGFβ2 was used at a final concentration of 25 pg/
ml (C-E) or 50 pg/ml (F), FGF-2 at 5 ng/ml (B,D)
or 20 ng/ml (F). Explants were photographed after a
total of 5 days of culture using Integrated Modula-
tion Contrast (A-E) or phase contrast (F). In the ab-
sence of growth factors (A), the cells remained in
the cobblestone array typical of the normal lens epi-
thelium. FGF alone (B), added on day 1, had no ap-
parent effect on cellular morphology. Addition of
TGFβ alone (C,E) induced elongation of cells and
extensive cell loss, exposing large regions of denuded
lens capsule (asterisk), while many bright, rounded,
dying cells were visible (C, arrow). At higher mag-
nification (E), cell surface blebbing (arrowheads) and
wrinkling of the lens capsule (arrow) were also evi-
dent. Generally, addition of FGF to TGFβ pretreated
explants prevented these morphological changes and
resulted in a marked reduction in the loss of cells
from the explant (D). In the explant depicted, the
capsule was almost completely covered with healthy
cells. In the TGFβ/FGF treated explant shown in F,
which was poorly covered with cells at the start of
the experiment and received higher doses of growth
factors, an isolated patch of monolayered cells piled
up into a thick plaque during culture, exposing the
underlying lens capsule (asterisk). The bar represents
90 µm.
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anti-rabbit antibody conjugated with Texas Red-X (Molecu-
lar Probes; 1:200) or Alexa 546 (Molecular Probes; 1:500).
Samples were counterstained with Hoechst dye (Sigma, St.
Louis, MO) and mounted using Vectashield (Vector,
Burlingame, CA). Under these conditions, immunoreactivity
was absent from controls in which antibodies were replaced
with corresponding nonimmune IgGs. For SEM, samples were
dehydrated with 100% ethanol, critical point dried, gold coated
and viewed using a Philips XL30 scanning electron micro-
scope.
RESULTS
Influence of FGF on cell loss in TGFβ treated explants: 3-5
day cultures:  When explants were cultured for 5 days with-
out addition of TGFβ, the cells generally retained their char-
acteristic epithelial morphology throughout culture (Figure 1A,
Table 1). Explants that received 5 ng/ml FGF on day 1 were
indistinguishable from control explants at this early stage of
culture (Figure 1B). In explants cultured with medium con-
taining 25 pg/ml TGFβ for one day followed by replacement
with control medium (Figure 1C,E), most explants exhibited
changes analogous to those reported in a previous study, in
which TGFβ containing medium was not replaced during cul-
ture and explants were cultured for 5 days with concentra-
tions of TGFβ2 ranging from 25-100 pg/ml [9]. Formation of
spindle-like cells began within 2-3 days, accompanied by wrin-
kling of the lens capsule (Table 1). Subsequently, cells showed
extensive cell surface blebbing, then rounded up and were lost
from the explant, exposing large regions of wrinkled lens cap-
sule (Figure 1C,E, Table 1). Addition of FGF to explants that
had been pretreated with TGFβ profoundly altered the out-
come (Figure 1D). Patchy spindle cell formation was observed
in some explants, but generally this was not accompanied by
wrinkling of the capsule, blebbing of the cell surface, or round-
ing up of cells, and most explants remained well covered with
cells (Table 1). When cell loss was observed, it was limited to
regions sparsely covered with cells on day 0 (not shown).
Immunolocalization studies showed that the cells salvaged
from TGFβ induced death by FGF were not normal lens epi-
thelial cells. Normal lens epithelial cells, but not mature fiber
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Figure 2. Immunolocalization of Pax6 and αSMA in whole mounts.  Explants were cultured without growth factors (A) or with 100 ng/ml
FGF-2 (B,C) for 3 days (A,B) or 8 days (C), or precultured for 1 day with 25 pg/ml TGFβ2 followed by 5 ng/ml FGF-2 and a further 4 days
of culture (D-F), or for 2 days with 75 pg/ml TGFβ without addition of FGF (G-I). Immunolocalization of Pax6 (A-C,F,I) and αSMA (E,H)
was carried out by a double labeling technique with Hoechst counterstaining of nuclei (D,G). D-F and G-I, each row represents images of the
same region. Strong nuclear reactivity for Pax6 was detected in explants cultured with a high, fiber differentiating dose of FGF on day 3 (B),
as in no growth factor controls (A), but reactivity was much weaker on day 8 (C). In TGFβ/FGF treated explants, although only low concen-
trations of each growth factor were used in this experiment, Pax6 reactivity was lost within 5 days of culture (F), while scattered cells
expressed αSMA (E). An explant fixed at an early stage of TGFβ induced transdifferentation is depicted in G-I. While many cells were
beginning to express αSMA, few exhibited the morphology characteristic of more mature spindle cells (indicated by arrowheads in H).
Nevertheless, virtually all nuclear reactivity for Pax6 had already been lost (I). The bar represents 60 µm in A-I.
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cells, characteristically express Pax6, a transcription factor
required for proper eye development [34]. Consistent with this,
substantial loss of immunoreactivity for Pax6 occurred be-
tween 3-8 days of culture (Figure 2A-C) when explants were
exposed to a high, fiber-differentiating dose of FGF [31,35].
However, treatment with TGFβ and then FGF, even at the low-
est concentration used in the present study, resulted in com-
plete loss of Pax6 reactivity within 5 days (Figure 2F,D). Some
of the surviving cells in TGFβ/FGF treated explants exhibited
reactivity for the myofibroblast marker αSMA (Figure 2E)
indicating that they had undergone an epithelial-mesenchy-
mal transition. Reactivity for αSMA, which is not expressed
in the normal lens [13,36], was not detectable in the control
and FGF treated explants depicted in Figure 2A-C. In another
experiment, it was shown that cells undergoing
transdifferentation in response to TGFβ alone lost reactivity
for Pax6 at an early stage of myofibroblast formation before
most of the cells expressing αSMA had achieved a spindle-
like morphology (Figure 2G-I).
Other growth factors known to evoke responses in lens
cells and likely to be encountered by them following cataract
surgery [35,37-43] were tested to determine whether they could
mimic the effects of FGF in promoting the survival of TGFβ
affected lens cells. Explants were pretreated with TGFβ at a
concentration of 50 pg/ml to ensure a strong TGFβ stimulus
and FGF, EGF, PDGF, IGF, or HGF was added on day 1. FGF,
EGF, and PDGF were used at a concentration of 10 ng/ml. At
this concentration, FGF and PDGF have comparable mitoge-
nic effects on rat lens epithelial explants [39], while EGF has
been shown to evoke responses in rabbit [40] and human [37]
lens epithelial cells and cultured rat lenses [41]. IGF was used
at 50 ng/ml, the half maximal dose established in a previous
rat lens explant study [35]. HGF was used at 20 ng/ml, con-
centrations of 5-20 ng/ml having been shown to stimulate pro-
liferation of rabbit [40] and human [42] lens epithelial cells.
Daily monitoring of the explants by phase contrast micros-
copy revealed that only FGF counteracted the loss of cells
induced by TGFβ and markedly suppressed the cellular
changes and capsular wrinkling that typically precede cell loss
(Figure 3 and Table 1). The inability of EGF, PDGF, and IGF
to prevent TGFβ induced cell loss, as reported in Table 1, was
confirmed in a supplementary experiment.
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Figure 3. Effects of FGF and other
growth factors on TGFβ induced cell
loss.  Lens epithelial explants were cul-
tured with 50 pg/ml TGFβ2 for 1 day,
then medium was replaced and explants
were cultured without further additions
(A) or with immediate addition of FGF
(B), EGF (C), PDGF (D), IGF (E), or
HGF (F). Growth factors were used at
the following final concentrations:
FGF-2, EGF and PDGF at 10 ng/ml,
IGF at 50 ng/ml, and HGF at 20 ng/ml.
The explants were photographed four
days later. Addition of FGF, but not the
other growth factors, prevented the
cells from undergoing typical TGFβ in-
duced changes that lead to cell death
and loss from the explant. In explants
treated with TGFβ alone (A) or TGFβ
plus growth factors other than FGF (C-
F), the wrinkled denuded lens capsule
was visible between rafts of abnormal
cells and scattered dying cells, whereas
the TGFβ/FGF treated explant (B) re-
mained covered with cells, including
some spindle-like cells (arrows). The
bar represents 180 µm.
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PCO-like characteristics of surviving cells: 11-31 day cul-
tures:  Because PCO-like changes occur progressively over
long periods following cataract surgery, additional experiments
involving long term culture were carried out. In addition, be-
cause the cells that have the greatest potential to impair vision
in PCO are those that grow out onto the posterior capsule,
towards the visual axis, higher doses of FGF (20-100 ng/ml)
were used to mimic the “fiber differentiating” stimulus of FGF
that lens cells receive as they pass into the posterior chamber
of the eye. FGF-2 at a concentration of 20 ng/ml has been
shown to be sufficient to induce the accumulation of the fiber
cell marker β-crystallin when re-added to explant cultures
every 5 days as in the present model (unpublished data). As
the long term behavior of “abnormal” TGFβ affected cells was
of primary interest in this study, TGFβ2 was used at 50-100
pg/ml to ensure cells received a strong stimulus [9]. Irrespec-
tive of the actual TGFβ/FGF dosage regime, the addition of
FGF invariably resulted in survival of TGFβ treated cells, as
reported above.
Expression of αSMA and fibronectin, markers for
myofibroblastic/fibroblastic transformation, was assessed in
whole mounts of explants cultured for 11 days with 50 pg/ml
TGFβ followed by 20 ng/ml FGF and in appropriate controls.
In the absence of growth factors, explants retained typical
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Figure 4. Immunolocalization of αSMA and fibronectin in explants cultured with TGFβ then FGF.  Lens epithelial explants were cultured for
one day without TGFβ2 (A-F) or with 50 pg/ml TGFβ (G-L) then medium was replaced and FGF-2 was added to D-L at a final concentration
of 20 ng/ml. Explants were cultured for a total of 11 days (A-I) or 31 days (J-L) with replacement of medium every fifth day, and re-addition
of FGF (D-L only). They were then fixed and processed as whole mounts for immunolocalization of αSMA (B,E,H,K) or fibronectin (C,F,I,L)
using a double labeling technique. Phase contrast images of corresponding regions are also included in each row (A,D,G,J). Explants cultured
for 11 days without addition of growth factors retained typical epithelial morphology (A) but scattered cells showed reactivity for αSMA (B)
and fibronectin (C). Cells in corresponding explants cultured with FGF alone were arrayed more irregularly (D) and no specific reactivity for
αSMA (E) and fibronectin (F) was detectable. TGFβ/FGF treated explants cultured in parallel contained abundant tightly packed cells with
occasional distinctive conglomerates of cells (G, arrow). The latter exhibited strong reactivity for both αSMA (H) and fibronectin (I) and
many cells in this region were spindle shaped (G-I). By 31 days of culture (J-L), cells in the TGFβ/FGF treated explant depicted gathered up
into a thick mound, leaving the surrounding lens capsule (Ca) denuded. Reactivity for αSMA (K) and fibronectin (L) was detectable. The bar
represents 75 µm in A-F and J-L and 150 µm in G-I.
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epithelial morphology, although scattered cells showed reac-
tivity for αSMA and fibronectin (Figure 4A-C). In correspond-
ing explants cultured with FGF alone, the cells exhibited neg-
ligible reactivity for these markers (Figure 4D-F). Spontane-
ous expression of αSMA during culture of lens explants with-
out growth factors (as in Figure 4B), which has been noted
previously [8,44], tends to occur when cell coverage is ini-
tially sparse. Release of endogenous TGFβ in response to cell
damage during explant preparation may underlie this phenom-
enon [23,24]. Such damage may arise during separation of the
fiber mass from the epithelium and/or during stretching and
pinning out the explant. Release of TGFβ from dying cells
may also contribute as culture proceeds. Suppression by FGF
of low level expression of αSMA in no growth factor control
explants, as reported here (Figure 4B,E), has also been noted
previously [8] but the mechanism is unknown.
No data for explants treated with TGFβ alone are included
in Figure 4, because when culture was prolonged beyond 5
days, TGFβ affected explants became completely denuded of
cells. Prior to cell death, cells in such explants typically ex-
hibit strong immunoreactivity for αSMA and fibronectin (not
shown) [8,11].
After 11 days of culture, TGFβ/FGF treated explants con-
tained abundant tightly packed cells with occasional distinc-
tive conglomerates of cells (Figure 4G), which contained
spindle shaped cells (Figure 4G-I) and exhibited strong reac-
tivity for both αSMA and fibronectin (Figure 4H,I). When the
culture period was extended to 31 days, surviving cells in some
TGFβ/FGF treated explants retracted into thick mounds or
plaques (Figure 4J), in which reactivity for αSMA and
fibronectin was detectable (Figure 4K,L). It was also noted
that in sparsely covered regions, isolated patches of
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Figure 5. Immunolocalization of various markers in sections of lens epithelial explants cultured with TGFβ then GF.  Lens epithelial explants
were cultured with TGFβ2 at a concentration of 50 pg/ml (A,C,D-F) or 100 pg/ml (B,G-L) for one day, then with 100 ng/ml FGF-2 for 21
days, as described in the Legend of Figure 4. At the end of the culture period, explants were fixed, embedded in paraffin and sectioned.
Sections were stained with hematoxylin-eosin (A,B) or processed for immunolocalization of collagen type I (C), or αSMA (E,H,K) and β-
crystallin (F,I,L), with Hoechst counterstaining of nuclei (D,G,J). In D-L, each row presents images of the same region. G-I and J-L are from
different regions of the same plaque. All images are arranged capsule surface downwards. In the explant shown in A, a thick multilayer of cells
covered the entire lens capsule, instead of the monolayer present in control explants and the normal lens. In the explant shown in B, the cells
mounded up into a plaque leaving regions of denuded capsule (arrowheads). In both cases, nuclei were sparse in some regions (A, B, arrow ),
indicating cell enlargement, and virtually all cells showed reactivity for type I collagen (as seen in C) and αSMA (E,H,K). In the explant that
remained covered with multilayered cells, strong reactivity for β-c ystallin was detected throughout the entire explant (F). In the explant that
exhibited plaque formation, reactivity for β-crystallin was particularly strong in one region of a plaque (I) but virtually absent from another
(L). The bar represents 85 µm.
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monolayered cells in some explants retracted from the lens
capsule into discrete plaques at a much earlier stage of cul-
ture. An explant in which formation of a plaque occurred within
5 days of culture is shown in Figure 1F. Note that, in contrast
to its inhibiting effect on the spontaneous expression of αSMA
and fibronectin in no-growth-factor controls (Figure 4B,C,E,F),
FGF did not prevent the expression of these proteins in ex-
plants exposed to an exogenous source of TGFβ (Figure
4H,I,K,L).
In another series of experiments, FGF was used at a con-
centration of 100 ng/ml to ensure a very strong fiber differen-
tiating stimulus, while TGFβ was used at 50 pg/ml, as above,
or at 100 pg/ml. Overall, irrespective of the growth factor con-
centrations used, two main types of response were consistently
observed in TGFβ/FGF treated explants cultured for 30-31
days, as illustrated in Figure 5. Formation of a multilayered
continuum of cells covering the lens capsule (Figure 5A,C,D),
or a gradual retraction of multilayered cells, usually begin-
ning on about day 15, into thick plaques or mounds surrounded
by denuded capsule (Figure 5B,G,J). The explant depicted in
Figure 5B was completely covered with viable cells at 4 days
of culture and no blebbing or other changes indicative of cell
death were observed throughout the culture period. In both
types of response, cell enlargement was evident in some re-
gions (Figure 5A,B). In contrast, in initially well covered con-
trol explants cultured without growth factors the capsule gen-
erally remains covered with a monolayer of cuboidal cells
(about 10 µm in diameter [31]; Figure 4A) as in the normal
lens.
Whether plaque formation occurred or not, most cells in
TGFβ/FGF treated explants exhibited reactivity for markers
for myofibroblastic/fibroblastic transformation, such as col-
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Figure 6. Morphological changes in lens epithelial explants cultured with TGFβ and FGF.  Explants were cultured without TGFβ (A,B) or with
TGFβ (C-F) for 1 day then without FGF (A) or with FGF (B-F). TGFβ2 was added at a final concentration of 100 pg/ml (C,D) or 50 pg/ml
(E,F) and FGF-2 at 100 ng/ml (B-D) or 20 ng/ml (E,F). Explants were cultured for 21 days (A-D) or 30 days (E,F) with change of medium
every 5 days and re-addition of FGF as before (B-F only), before fixing and processing for SEM. Explants cultured without addition of growth
factors retained the cobblestone morphology typical of the normal lens epithelium (A). A corresponding explant cultured with FGF alone
showed elongation of cells consistent with FGF induced fiber differentiation (B), whereas a TGFβ/FGF treated explant cultured in parallel
exhibited formation of small plaques (C,D, arrows) and spindle-like cells (C, arrowhead). Although this explant was generally well covered
with cells, a region of denuded capsule can be seen (C, asterisk). The surface of one plaque was relatively smooth (C), whereas the surface of
a nearby plaque (D) was irregular with small, globular protrusions (D, arrowhead). A TGFβ/FGF treated explant from another experiment is
shown in E. In this explant, cells retracted into thick mounds during extended culture leaving large regions of the lens capsule denuded (E,
asterisk). At higher magnification, the cellular surface of this explant was seen to be covered with a thick web of extracellular matrix- ike
material (F). The bar represents 50 µm in A,B, 20 µm in C,D, 100 µm in E, and 10 µm in F.
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lagen type I (Figure 5C), αSMA (Figure 5E,H,K), and
fibronectin (not shown). In addition, using a double labeling
technique, many cells were shown also to strongly express
the lens fiber cell protein β-crystallin (Figure 5F,I). However,
β-crystallin was not present in all cells, even though FGF was
used at a very high concentration in this experiment. For ex-
ample, adjacent sections of a single plaque were found to be
positive and negative for β-crystallin (Figure 5I,L). Thus, two
populations of cells appeared to be present in these explants.
Most cells simultaneously expressed markers for both TGFβ
induced transdifferentiation and normal lens fiber differentia-
tion, but some cells expressed only the transdifferentiation
markers.
SEM of long term cultures of TGFβ/FGF-treated explants
is shown in Figure 6. In an explant cultured in parallel with
explants shown in Figure 5, in which only a slight retraction
of cells from the capsule occurred during culture, occasional
discrete plaques of cells were observed (Figure 6C,D). Spindle
shaped cells were also evident (Figure 6C). Plaques and
spindle-like cells did not develop in explants cultured without
addition of growth factors or with FGF alone (Figure 6A,B).
As indicated above, in other explants cells gathered up into
mounds during extended culture. SEM of one such explant
revealed that the explant surface was extensively covered with
a meshwork of ECM-like material (Figure 6E,F).
Overall, results were similar for all treatment regimes used
in these long term experiments. However, because there was
considerable between-explant variation within each treatment
group, any dose related effects would have been difficult to
discern. The number and/or distribution of cells present on
each explant initially is possibly an important factor underly-
ing this between-explant variation, as illustrated by the atypi-
cal response that occurred in the sparsely covered explant
shown in Figure 1F.
DISCUSSION
 Studies in various species now point to a role for TGFβ in the
etiology of PCO [8-10,16,17,45]. Morphologically, there are
close parallels between changes associated with human PCO
[3,5,45,46] and changes induced by TGFβ (formation of
spindle shaped myofibroblasts, wrinkling of the lens capsule,
and abnormal deposition of ECM). Moreover, mesenchymal
cell proteins not normally expressed in the lens but found in
human [20,45,47-50] and rabbit [51] PCO are also induced by
TGFβ in lens cells in vitro and in vivo [8,11,14,15,17]. These
include the cytoskeletal protein αSMA, expressed by
myofibroblasts, and ECM proteins, such as fibronectin, types
I and III collagen, and tenascin.
Following cataract surgery, potential contributors of TGFβ
to the lens cell environment include the fluids that bathe the
lens (aqueous and vitreous) [9,18], inflammatory cells that ac-
cumulate in the post operative period [21,47], and the lens
cells themselves [10,16,17,19,20,22]. Significantly, it has been
shown that TGFβ dependent Smad signaling is stimulated by
damaging the mouse or human lens epithelium [23,24]. Such
damage would occur during cataract surgery. While lens cells
are responsive to all three mammalian isoforms, TGFβ2 is the
form most likely to be available to lens cells post cataract sur-
gery [10,17,18,23].
Another characteristic effect of TGFβ on lens cells is in-
duction of apoptosis, as shown in studies of rat lens epithelial
explants [7,9,28], human lens cells [26], cultured rodent lenses
[25,27], and transgenic mice [28]. TUNEL-positive, apoptotic
c lls have also been localized in human PCO, especially dur-
ing the early post-operative period [27]. Similarly, in rabbits
subjected to cataract surgery, residual lens cells become αSMA
positive, then undergo apoptotic cell death within 10 days
[51,52].
Typically, in lens epithelial explants from rats that are 13
days old or more, TGFβ induces cells to undergo apoptotic
cell death, as indicated by cell surface blebbing, nuclear py-
knosis and fragmentation, and the presence of TUNEL-posi-
tive cells [7,9,28]. Within a relatively short time, virtually all
cells exhibit cell surface blebbing then round up and detach
from the explant (Table 1). The present study has established
that FGF-2 counteracts this TGFβ induced cell loss. In addi-
tion, daily monitoring by phase contrast microscopy revealed
that adding FGF to TGFβ treated explants resulted in almost
complete suppression of the cell surface blebbing that typi-
cally precedes TGFβ induced cell loss, while rounded, dying
cells were rarely observed. Further, all cells that survived were
TGFβ affected as evidenced by the fact that all cells in TGFβ/
FGF treated explants lost the epithelial marker Pax6 at a much
faster rate than could be accounted for by loss associated with
FGF-induced fiber differentiation (Figure 2). Thus FGF does
not appear to counter cell loss simply by inducing prolifera-
tion of normal lens epithelial cells to replace those lost by
TGFβ induced apoptosis. Rather, FGF appears to be prevent-
ing apoptosis of cells that have transdifferentiated in response
to TGFβ.
FGF-2 is a potent mitogen not only for normal lens epi-
thelial cells [31,35] but also for fibroblasts and myofibroblasts
[53]. The increase in cell numbers associated with the exten-
sive multilayering and plaque formation that occurred during
long term culture of TGFβ/FGF treated explants, long after
exposure of the cells to exogenous TGFβ, suggests that FGF
may be exerting a supplementary mitogenic role under these
experimental conditions.
Several other growth factors, used at concentrations pre-
viously shown to exert biological effects on rat or human lens
epithelial cells [35,37,39-42], were unable to mimic the ef-
fects of FGF in the present study. Thus the action of FGF in
counteracting TGFβ induced cell loss under these conditions
appears to be specific. Note that FGF also differs from other
growth factors in terms of its distinctive ability to induce lens
epithelial cells to undergo normal fiber differentiation [31,54].
However, this study has shown that doses of FGF-2 ranging
from 5 ng/ml to 100 ng/ml are effective in promoting cell sur-
vival. The lower dose is capable of inducing cell proliferation
and migration in normal lens cells but induction of fiber dif-
ferentiation requires doses greater than 10 ng/ml [31,35].
In the present study, TGFβ and FGF were added sequen-
tially to ensure that cells had the opportunity to respond to
TGFβ prior to exposure to FGF. However, simultaneous addi-
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tion of 50 pg TGFβ2 and 20 ng/ml FGF-2 to freshly prepared
explants has also been shown to result in survival of abnormal
cells that exhibit characteristics analogous to those described
here (unpublished data).
Interestingly, FGF-2 has been shown to protect human
lens epithelial cells against apoptosis induced by serum depri-
vation [55]. This effect is independent of its ability to enhance
cell proliferation and fiber differentiation and appears to be
mediated by upregulation of the proto-oncogene inhibitor of
apoptosis, bcl-2. Furthermore, endogenous FGF-1 has been
shown to be a survival factor for serum deprived bovine lens
cells, an effect that is also independent of its mitogenic poten-
tial [56].
In contrast to the present findings, in studies of residual
lens cells in human lens capsular bags prepared from post
mortem eyes [17] addition of TGFβ, without addition of FGF,
did not lead to complete loss of TGFβ affected cells from the
lens capsule. However, it has been shown that both human
capsular bags [57] and samples of lens capsule obtained at
cataract surgery [58] release FGF-2 into the medium during
culture, at concentrations capable of promoting extensive pro-
liferation of adhering lens cells. Thus the apparent lack of re-
quirement for FGF for cell survival in the human study de-
scribed above [17] may have been due to the release of en-
dogenous FGF during culture. The high explant/medium vol-
ume ratio in the latter system [57], compared to the rat ex-
plant model, would favor the accumulation of effective levels
of endogenous FGF.
In TGFβ/FGF treated rat lens explants, the rapid loss of
expression of Pax6, described above, strongly suggests that
the majority of cells that survive are not normal lens epithelial
cells. Further support for this conclusion comes from the find-
ing that the myofibroblast/fibroblast markers, αSMA,
fibronectin, and type I collagen were expressed in TGFβ/FGF
treated explants, with reactivity detectable in virtually all cells
in some explants. The strong reactivity for the fiber differen-
tiation marker β-crystallin [31] exhibited by most cells in such
explants suggests that an aberrant form of fiber differentia-
tion can occur under these conditions. However, β-crystallin
was not detected in all cells even when a particularly high
dose of FGF (100 ng/ml) was used to ensure cells received a
very strong fiber differentiation stimulus [31,35]. Thus there
is no obligatory link between FGF induced cell survival and
β-crystallin induction. This is consistent with the finding that
survival can be promoted by a low, non-fiber-differentiating
dose of FGF (Figure 1D). Also, reactivity for αSMA was ex-
hibited both by cells that expressed β-crystallin and those that
did not, indicating that cells rescued by FGF treatment repre-
sent, or have the potential to give rise to, a heterogeneous popu-
lation of abnormal cells.
Little is known about absolute concentrations of FGFs in
the ocular media that bathe the lens. In any case, “average”
values such studies provide may not accurately reflect local
concentrations available to lens cells in regions where they
normally receive a strong FGF stimulus, for example, near
the lens equator [31]. In the rabbit, FGF-2 concentrations have
been shown to increase in the aqueous after cataract surgery
[59,60] and concentrations as high as 30-50 ng/ml FGF-2 have
been reported in human vitreous from patients with diabetic
retinopathy [61]. In the majority of experiments in the present
study, a fiber differentiating dose of FGF was used (20 ng/ml
or more) [31,35], the rationale being that cells that give rise to
human PCO on the posterior capsule are likely to receive a
strong FGF stimulus.
PCO is associated with two distinctive types of outgrowth
of lens cells onto the posterior capsule; fibrous and “pearl-
like” [3,6]. These are readily distinguishable in situ [6] and
both types may occur in the same patient. The fibrous form
consists of strands and undulating arrays of fibroblastic cells
(generally obscured by a thick covering of ECM) and regions
of posterior capsule are often visible between the cells. In the
pearl-like form, large rounded or ovoid structures, often termed
“Elschnig’s pearls”, are distributed over the posterior capsule
[3,5,6]. In the present study, TGFβ/ GF treated explants ex-
hibited many of the features of these forms of PCO. For ex-
ample, the explant depicted in Figure 6E,F with its strands
and mounds of abnormal cells covered with heavy deposits of
ECM-like material is highly analogous to fibrous PCO, as is
the tendency, noted in this and other explants, for cells to
mound up into plaques with regression of cells from adjacent
areas of the lens capsule as culture proceeds [45]. Such fea-
tures have not been noted in previous studies in vitro of PCO
related changes.
The distinctive appearance of pearl-like PCO has been
variously ascribed to clusters or layers of swollen, “bladder”
cells [3-5] and pearl-like globules (25-75 µm by SEM [5]),
which are thought to represent an aberrant form of fiber dif-
ferentiation [3,5]. TGFβ/FGF treated explants also exhibited
features of this form of cataract, including clumps or continu-
ous layers of abnormal cells containing enlarged or “swollen”
cells (Figure 5), and small plaques of cells (about 60 µm in
diameter) arising out of a continuous, relatively ECM free layer
of cells (Figure 6). Again these are features of PCO that have
not been noted in previous studies in vitro. Moreover, the co-
localization of protein markers found in human PCO [45,47-
50] with β-crystallin in such explants is consistent with the
putative link between “pearl” formation and abnormal fiber
differentiation.
Others have proposed that FGF influences PCO outcome
and that FGF inhibitors may be useful therapeutically, solely
on the basis of its proliferative effect on lens cells [57,58].
The present study adds considerable weight to these sugges-
tions by revealing a potential role for FGF in ensuring the
survival of lens cells that have undergone myofibroblastic/
fibroblastic transformation during PCO development. This
study also reports for the first time that FGF in conjunction
with TGFβ promotes cellular behavior such as excessive ECM
production, multilayering, and plaque formation that are known
to contribute to visual loss due to PCO.
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